Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMA5DDI)

Drug Name

NGM707 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Phase 2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Leukocyte immunoglobulin-like receptor B2 (LILRB2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MK-4830	DMCT37W	Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]
------------------------------------------------------------------------------------

Drug(s) Targeting Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
SAR444881	DM105TB	Aggressive cancer	2A00-2F9Z	Phase 1	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Leukocyte immunoglobulin-like receptor B2 (LILRB2)	TTHC6XU	LIRB2_HUMAN	Antagonist	[2]
Leukocyte immunoglobulin-like receptor subfamily B member 1 (LILRB1)	TTC0QRJ	LIRB1_HUMAN	Antagonist	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT04913337) A Phase 1/2 Dose Escalation/Expansion Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies. U.S.National Institutes of Health.
2	Clinical pipeline report, company report or official report of NGM Biopharma
3	National Cancer Institute Drug Dictionary (drug name MK4830).
4	Clinical pipeline report, company report or official report of Sanofi